| Autor: |
Maura L, Gillison, Robert L, Ferris, Jonathan, Harris, A Dimitrios, Colevas, Loren K, Mell, Christina, Kong, Richard C, Jordan, Kevin L, Moore, Minh-Tam, Truong, Claudia, Kirsch, Arnab, Chakravarti, Dukagjin M, Blakaj, David A, Clump, James P, Ohr, John F, Deeken, Michael F, Gensheimer, Nabil F, Saba, Jennifer A, Dorth, David I, Rosenthal, Rom S, Leidner, Randall J, Kimple, Mitchell, Machtay, Walter J, Curran, Pedro, Torres-Saavedra, Quynh Thu, Le |
| Rok vydání: |
2022 |
| Zdroj: |
International journal of radiation oncology, biology, physics. |
| ISSN: |
1879-355X |
| Popis: |
Programmed death-1 immune checkpoint blockade improves survival of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but the benefits of addition to (chemo)radiation for newly diagnosed patients with HNSCC remain unknown.We evaluated the safety of nivolumab concomitant with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1), every 3-week cisplatin (arm 2), cetuximab (arm 3), or alone for platinum-ineligible patients (arm 4) in newly diagnosed intermediate- or high-risk locoregionally advanced HNSCC. Patients received nivolumab from 2 weeks prior to radiation therapy until 3 months post-radiation therapy. The primary endpoint was dose-limiting toxicity (DLT). If ≤2 of the first 8 evaluable patients experienced a DLT, an arm was considered safe. Secondary endpoints included toxicity and feasibility of adjuvant nivolumab to 1 year, defined as all 7 additional doses received by ≥4 of the first 8 evaluable patients across arms.Of 39 patients (10 in arms 1, 3, 4 and 9 in arm 2), 72% had T3-4 tumors, 85% had N2-3 nodal disease, and 67% had10 pack-years of smoking. There were no DLTs in arms 1 and 2, 1 in arm 3 (mucositis), and 2 in arm 4 (lipase elevation and mucositis in 1 and fatigue in another). The most common grade ≥3 nivolumab-related adverse events were lipase increase, mucositis, diarrhea, lymphopenia, hyponatremia, leukopenia, fatigue, and serum amylase increase. Adjuvant nivolumab was feasible as defined in the protocol.Concomitant nivolumab with the 4 tested regimens was safe for patients with intermediate- and high-risk HNSCC, and subsequent adjuvant nivolumab was feasible as defined (NCT02764593). |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
